|
|
 | Providers > About LungSign™ |
About LungSign™ |
|
LungSign™ — new hope for early detection
LungSign™ is a safe, painless and convenient test to assess a patient's risk of lung cancer. LungSign™ is based on an innovative marker in sputum that is highly correlated with the presence of lung malignancy — even in early stage, presymptomatic disease.
As such, LungSign™ is the first test to market that provides both an independent result to help with the early detection of lung cancer and a useful complement to current radiological diagnostic methods. For example, LungSign™ can be used to further define the cancer risk of patients with small, CT-detected nodules, by adding a biological measure of malignancy.
The patients for whom LungSign™ is expected to bring benefit include:
• Patients suspicious for lung cancer (see indications below) or those being considered for CT screening
• Post-CT patients seeking assessment of malignant potential of nodules of undetermined significance
• Patients for whom radiation from CT or x-ray should be limited (e.g., women at risk for breast cancer, female smokers, or lung cancer survivors)
• Lung cancer survivors monitoring for recurrence
• Patients in need of motivation-related smoking cessation tools
Indications for use
LungSign is indicated for the evaluation of high risk patients suspicious for lung cancer due to their:
• Age — over 50 years
• Significant smoking history (over 20 pack-years) or significant exposure to carcinogens
• Symptomology or clinical suspicion for lung cancer
LungSign™ may benefit high-risk patients of both sexes, in particular: smokers, former smokers, and individuals exposed to industrial and environmental carcinogens.
LungSign™ has not been validated for patients who have received chemotherapy or radiotherapy. In addition it has not been validated for patients who harbor cancers other than lung cancer.
LungSign™ in Practice
LungSign™ should be requested and interpreted under the care of a physican. LungSign™ sample collection kits are orderable at Order LungSign™ Now.
The LungSign™ test consists of a sputum specimen collection kit (used by patients in the privacy of their homes), and, after the laboratory analysis is complete, a specimen testing report and interpretation guide, sent directly to the patient’s physician. The turn-around for delivery of reports is typically two weeks.
next >
|
|
| |
|
| |
LungSign™ is a safe, simple and convenient test to assess your risk for lung cancer. | |
|
|
| | Perceptronix is a cancer diagnostic service company focused on detecting cancer at early stages to improve patient outcomes.
| |
|